# US 2003/0216431 A1 · Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216431 A1
- Document ID: US20030216431A1
- Status: Published application
- Kind: A1
- Application number: 10/209,837
- Filed: 2002-08-01
- Published: 2003-11-20
- Earliest claimed: 2002-05-17
- Inventors: Rajeev Raut
- Web page: https://patentgrep.com/patent/US20030216431A1

## CPC

- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 27/02: Ophthalmic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to novel ophthalmic pharmaceutical compositions comprising an inflammation-treating amount of a 4-aminoquinoline compound, derivative, isomers, or chemical salts, and methods for using these compositions for the treatment of ocular inflammatory conditions by topical administration directly to the eye.

## Claims

### Claim 1

An ophthalmic pharmaceutical composition comprising a pharmaceutically acceptable ophthalmic carrier and an ocular inflammation-treating amount of a 4-aminoquinoline compound of formula I: ##STR11## wherein
4
A is ##STR12##, —(C(R.sup.3)(R.sup.4)).sub.n—;
5
or
A is ##STR13## or (C.sub.5-C.sub.6)-cycloalkylene; n is 1-4;
6
or
A is an alkyl of 1 through 5 carbon atoms substituted by a dialkylamino group of which each alkyl radical contains 1 through 4 carbon atoms, phenyl, or phenyl substituted by one or more radicals selected from carboxy and hydroxy and alkyl radicals of 1 through 4 carbon atoms and R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl;
and
R.sup.1 to R.sup.6 are hydrogen or in which one or two of R.sup.1 to R.sup.6 are independently selected from alkyl and the other substituents are hydrogen; R.sup.7 and R.sup.8 are independently selected from alkyl, alkenyl or aralkyl, or together with the N atom signify pyrrolidine or piperidine, either or both of which may be substituted by alkyl; and n=0 or 1; or
wherein R.sup.1 and R.sup.3 are tri- or tetramethylene; R.sup.2 and R.sup.4 to R.sup.6 are hydrogen; n=0; and R.sup.7 and R.sup.8 are defined as above; or
wherein R.sup.1 and R.sup.7 are methylene or dimethylene and n=1, or
R.sup.3 and R.sup.7 are di- or trimethylene and n=0, or
R.sup.3 and R.sup.7 are di- or trimethylene and n=1, or
R.sup.3 and R.sup.7 are tri- or tetramethylene and n=0, or
R.sup.5 and R.sup.7 are tri- or tetramethylene and n=1, or
R.sup.1 and R.sup.5 are di- or tri-methylene and n=1, and the remaining substituents are hydrogen, except R.sup.8 which is selected from alkyl, alkenyl or alkynyl; or
wherein R.sup.3 and R.sup.5 are tri-or tetramethylene and n=1; R.sup.1, R.sup.2, R.sup.4 and R.sup.6 are hydrogen; and R.sup.7 and R.sup.8 are selected from alkyl, alkenyl or aralkyl or together with the N atom are pyrrolidine or piperidine, either or both of which may be substituted by alkyl;
R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl;
R.sup.11 is a hydrogen atom or an alkyl radical (1-5 carbon atoms);
or
R.sup.7 is hydrogen and R.sup.8 is (CH.sub.2)sub.p-B and p is 1-3;
B is aryl selected from phenyl, phenyl mono-, di-, or tri-substituted by substituent from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, trifluoromethyl, cyano, di-lower alkylamino or their N-oxides, phenyloxy, phenyl, and methylsuphanyl, naphthyl, benzo>1,3!dioxol, or monocyclic aromatic heterocycle with 1 or 2 heteroatoms selected from N and O;
and
R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl; as well as pharmaceutically acceptable salts of basic compounds of formula I.

### Claim 2 (depends on 1)

An ophthalmic pharmaceutical composition according to claim 1 wherein
A is ##STR12##, —(C(R.sup.3)(R.sup.4)).sub.n—.
R.sup.1 to R.sup.6 are hydrogen or in which one or two of R.sup.1 to R.sup.6 are independently selected from alkyl and the other substituents are hydrogen; R.sup.7 and R.sup.8 are independently selected from alkyl, alkenyl or aralkyl, or together with the N atom signify pyrrolidine or piperidine, either or both of which may be substituted by alkyl; and n=0 or 1; or
wherein R.sup.1 and R.sup.3 are tri- or tetramethylene; R.sup.2 and R.sup.4 to R.sup.6 are hydrogen; n=0; and R.sup.7 and R.sup.8 are defined as above; or
wherein R.sup.1 and R.sup.7 are methylene or dimethylene and n=1, or
R.sup.3 and R.sup.7 are di- or trimethylene and n=0, or
R.sup.3 and R.sup.7 are di- or trimethylene and n=1, or
R.sup.3 and R.sup.7 are tri- or tetramethylene and n=0, or
R.sup.5 and R.sup.7 are tri- or tetramethylene and n=1, or
R.sup.1 and R.sup.5 are di- or tri-methylene and n=1, and the remaining substituents are hydrogen, except R.sup.8 which is selected from alkyl, alkenyl or alkynyl; or
wherein R.sup.3 and R.sup.5 are tri-or tetramethylene and n=1; R.sup.1, R.sup.2, R.sup.4 and
R.sup.6 are hydrogen; and R.sup.7 and R.sup.8 are selected from alkyl, alkenyl or aralkyl or together with the N atom are pyrrolidine or piperidine, either or both of which may be substituted by alkyl;
R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl;
R.sup.11 is a hydrogen atom or an alkyl radical (1-5 carbon atoms); or the pharmaceutically acceptable salts of the above compounds.

### Claim 3 (depends on 1)

An ophthalmic pharmaceutical composition according to claim 1 wherein
A is ##STR13##
7
or (C.sub.5-C.sub.6)-cycloalkylene; n is 1-4;
R.sup.3 and R.sup.4 are each independently hydrogen or methyl;
R.sup.7 is hydrogen and R.sup.8 is (CH.sub.2)sub.p-B and p is 1-3;
B is aryl selected from phenyl, phenyl mono-, di-, or tri-substituted by substituent from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, trifluoromethyl, cyano, di-lower alkylamino or their N-oxides, phenyloxy, phenyl, and methylsuphanyl, naphthyl, benzo>1,3!dioxol, or monocyclic aromatic heterocycle with 1 or 2 heteroatoms selected from N and O;
R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl; as well as pharmaceutically acceptable salts of basic compounds of formula I, wherein when A is —(C(R.sup.3)(R.sup.4)).sub.n—.

### Claim 4 (depends on 1)

An ophthalmic pharmaceutical composition according to claim 1 wherein
A is an alkyl of 1 through 5 carbon atoms substituted by a dialkylamino group of which each alkyl radical contains 1 through 4 carbon atoms, phenyl, or phenyl substituted by one or more radicals selected from carboxy and hydroxy and alkyl radicals of 1 through 4 carbon atoms and R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl; or the pharmaceutically acceptable salts of of basic compounds of formula I.

### Claim 5 (depends on 2)

An ophthalmic pharmaceutical composition according to claim 2 wherein said 4-aminoquinoline compound is selected from the group consisting of:
N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-dimethyl-ethane-1,2-diamine,
N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-diethyl-ethane-1,2-diamine,
N.sub.3-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-dimethyl-propane-1,3-diamine,
N.sub.3-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-diethyl-propane-1,3-diamine,
(RS)(7-chloro-quinolin-4-yl)-(1-methyl-pyrrolidin-2-yl-methyl)-amine,
(RS)(7-chloro-quinolin-4-yl)-(1-ethyl-piperidin-3-yl)-amine,
or the pharmaceutically acceptable salts of these compounds.

### Claim 6 (depends on 2)

An ophthalmic pharmaceutical composition according to claim 2 wherein said 4-aminoquinoline compound is selected from the group consisting of:
(RS)-N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-dimethyl-propane-1,2-diamine,
(RS)-N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-diethyl-propane-1,2-diamine,
(S)-N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-diethyl-propane-1,2-diamine,
(R)-N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-diethyl-propane-1,2-diamine,
(RS)-(7-chloro-quinolin-4-yl)-(1-methyl-2-pyrrolidin-1-yl-ethyl)-amine,
(R)-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2,N.sub.2-dimethyl-propane-1,2-diamine,
(S)-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2,N.sub.2-dimethyl-propane-1,2-diamine,
or the pharmaceutically acceptable salts of these compounds.

### Claim 7 (depends on 2)

An ophthalmic pharmaceutical composition according to claim 2 wherein said 4-aminoquinoline compound is selected from the group consisting of:
(S)-N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-dimethyl-propane-1,2-diamine,
(R)-N.sub.2-(7-chloro-quinolin-4-yl)-N.sub.1,N.sub.1-dimethyl-propane-1,2-diamine,
N.sub.1-(7-chloro-quinolin-4-yl)-2,N.sub.2,N.sub.2-trimethyl-propane-1,2-diamine,
(RS)-(7-chloro-quinolin-4-yl)-(1-methyl-pyrrolidin-3-yl)-amine,
or the pharmaceutically acceptable salts of these compounds.

### Claim 8 (depends on 3)

An ophthalmic pharmaceutical composition according to claim 3, wherein B is selected from the group consisting of phenyl; naphthyl; benzo>1,3!dioxol and phenyl substituted with from 1-3 substituents selected from the group consisting of halogen, hydroxy, lower-alkyl, lower-alkoxy, trifluoromethyl, cyano, di-lower-alkyl-amino, N-oxides of di-lower-alkyl-amino, phenyloxy, phenyl and methylsulphanyl.

### Claim 9 (depends on 3)

An ophthalmic pharmaceutical composition according to claim 3, wherein R.sup.9 is hydrogen, R.sup.10 is chlorine, p is 1 or 2, A is —CH.sub.2C(CH.sub.3).sub.2— and B is a benzene ring which is mono-, di- or tri-substituted.

### Claim 10 (depends on 3)

An ophthalmic pharmaceutical composition according to claim 3, wherein said 4-aminoquinoline compound is selected from the group consisting of
N.sub.1-(7-Chloro-quinolin-4-yl)-N.sub.2-(3-chloro-benzyl)-2-methyl-propane-1,2-diamine,
N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2-(2-hydroxy-3-methoxy-benzyl)-2-methyl-propane-1,2-diamine,
N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2-(2-hydroxy-5-methoxy-benzyl)-2-methyl-propane-1,2-diamine,
N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2-(4-hydroxy-3-methoxy-benzyl)-2-methyl-propane-1,2-diamine,
N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2(benzyl)-2-methyl-propane-1,2-diamine,

### Claim 11 (depends on 3)

An ophthalmic pharmaceutical composition according to claim 3, wherein R.sup.9 is hydrogen, R.sup.10 is chlorine, p is 1, A is cyclohexane-1,2-diyl or cyclohexane-1,4-diyl and B is a benzene ring which is unsubstituted or mono- or di-substituted.

### Claim 12 (depends on 11)

An ophthalmic pharmaceutical composition according to claim 11, wherein said 4-aminoquinoline compound is selected from the group consisting of
(1S,2S)-N.sub.1-(7-Chloro-quinolin-4-yl)-N.sub.2-(benzyl)-cyclohexane-1,2-diamine,
(1S,2S)-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2-(4-chloro-benzyl)-cyclohexane-1,2-diamine,
(1S,2S)-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.2-(4-dimethylamino-benzyl)-cyclo-hexane-1,2-diamine
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(4-dimethylamino-benzyl)-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(benzyl)-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(3-chloro-benzyl)-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(2-hydroxy-4-methoxy-benzyl)-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(3,5-dimethoxy-benzyl)-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(4-methylsulphanyl-benzyl)-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(4-diethylamino-benzyl)-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(biphenyl-4-ylmethyl)-cyclohexane-1,4-diamine,
trans-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4->2-(3,5-dimethoxy-phenyl)-ethyl!-cyclohexane-1,4-diamine,
cis-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(4-methoxy-benzyl)-cyclohexane-1,4-diamine,
trans-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(4-dimethylamino-benzyl)-cyclohexane-1,4-diamine and trans-N.sub.1-(7-chloro-quinolin-4-yl)-N.sub.4-(2,6-difluoro-benzyl)-cyclohexane-1,4-diamine.

### Claim 13 (depends on 4)

An ophthalmic pharmaceutical composition according to claim 4 wherein said 4-aminoquinoline compound is selected from the group consisting of:
Chloroquine phosphate
Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, sulfate,
Quinoline, 4-((4-(bis(2-chloroethyl)amino)-1-methylbutyl)amino)-7-chloro-, dihydrochloride N,N-Dideethylchloroquine,
Quinoline, 4-(2-(bis(2-chloroethyl)amino)ethylamino)-7-chloro-, dihydrochloride, monohydrate,
Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, diphosphate, (-)-,
Quinoline, 4-(p-bis(2-chloroethyl)aminophenylethylamino)-7-chloro-, monohydrochloride
Chloroquine
3-Methylchloroquine
Salicylic acid, 4-acetamido-, compd. with 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline,
Hydroxychloroquine
Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, mixed with sodium nitrite
Hydroxychloroquine sulfate,
Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, diphosphate,
Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, phosphate,
Desethylchloroquine.
Chloroquine hydrochloride,
L-Ascorbic acid, compd. with N(sup 4)-(7-chloro-4-quinolinyl)-N(sup 1),N(sup 1)-diethyl-1,4-pentanediamine,
N,N-Dideethylchloroquine
Amodiaquine

### Claim 13

An ophthalmic pharmaceutical composition comprising a pharmaceutically acceptable ophthalmic carrier and an ocular inflammation-treating amount of a 4-aminoquinolone compound selected from the group consisting of mefloquine, quinacrine (mepacrine), pyrimethamine, and cletoquine.

### Claim 14

An ophthalmic pharmaceutical composition comprising a pharmaceutically acceptable ophthalmic carrier and an ocular inflammation-treating amount of a 4-aminoquinolone compound further comprising one or more additional ophthalmic pharmaceutical compositions.

### Claim 15 (depends on 14)

An ophthalmic pharmaceutical composition of claim 14 wherein said composition is formulated as a suspension, solution, salve, ointment, spray, liposomal composition, nanoemulsion particle composition, or chitosan particle composition.

### Claim 16 (depends on 14)

The ophthalmic pharmaceutical composition of claim 14 wherein said additional one or more ophthalmic pharmaceutical compositions are selected from the group consisting of buffers, surfactants, preservatives, and ophthalmic wetting agents, tonicity imparting agents, viscosity imparting agents, suitable absorption enhancers, stabilizing agents, metal chelating agents, or drug solubility enhancers, such used in the treatment of the eye.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein said wetting agent is carboxymethylcellulose, hydroxypropyl methylcellulose, glycerin, mannitol, polyvinyl alcohol or hydroxyethylcellulose and the diluting agent is water, distilled water, sterile water, or artificial tears, wherein the wetting agent is present in an amount of about 0.001% to about 10%.

### Claim 18 (depends on 14)

The ophthalmic pharmaceutical composition of claim 14 wherein said one or more additional active ophthalmic pharmaceutical compositions are selected from the group consisting of anti inflammatory agents, antibiotics, anti fungals, amd anti virals, local anaesthetic agents, cycloplegics, ocular hypotensives, or pupillary dilators used in the treatment of the eye.

### Claim 19

A method for treating ocular inflammation comprising topically applying to the eye an ophthalmic pharmaceutical composition comprising a pharmaceutically acceptable ophthalmic carrier and an ocular inflammation-treating amount of one or more 4-aminoquinoline compounds, or one of their pharmaceutically acceptable analogues or salts.

### Claim 20 (depends on 19)

The method of claim 19 wherein said 4-aminoquinoline derivative is a compound of formula I: ##STR11## wherein
A is
8
##STR12##, —(C(R.sup.3)(R.sup.4)).sub.n—;
or
A is ##STR13## or (C.sub.5-C.sub.6)-cycloalkylene; n is 1-4;
9
or
A is an alkyl of 1 through 5 carbon atoms substituted by a dialkylamino group of which each alkyl radical contains 1 through 4 carbon atoms, phenyl, or phenyl substituted by one or more radicals
10
selected from carboxy and hydroxy and alkyl radicals of 1 through 4 carbon atoms and R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl;
and
R.sup.1 to R.sup.6 are hydrogen or in which one or two of R.sup.1 to R.sup.6 are independently selected from alkyl and the other substituents are hydrogen; R.sup.7 and R.sup.8 are independently selected from alkyl, alkenyl or aralkyl, or together with the N atom signify pyrrolidine or piperidine, either or both of which may be substituted by alkyl; and n=0 or 1; or
wherein R.sup.1 and R.sup.3 are tri- or tetramethylene; R.sup.2 and R.sup.4 to R.sup.6 are hydrogen; n=0; and R.sup.7 and R.sup.8 are defined as above; or
wherein R.sup.1 and R.sup.7 are methylene or dimethylene and n=1, or
R.sup.3 and R.sup.7 are di- or trimethylene and n=0, or
R.sup.3 and R.sup.7 are di- or trimethylene and n=1, or
R.sup.3 and R.sup.7 are tri- or tetramethylene and n=0, or
R.sup.5 and R.sup.7 are tri- or tetramethylene and n=1, or
R.sup.1 and R.sup.5 are di- or tri-methylene and n=1, and the remaining substituents are hydrogen, except R.sup.8 which is selected from alkyl, alkenyl or alkynyl; or
wherein R.sup.3 and R.sup.5 are tri-or tetramethylene and n=1; R.sup.1, R.sup.2, R.sup.4 and R.sup.6 are hydrogen; and R.sup.7 and R.sup.8 are selected from alkyl, alkenyl or aralkyl or together with the N atom are pyrrolidine or piperidine, either or both of which may be substituted by alkyl;
R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl;
R.sup.11 is a hydrogen atom or an alkyl radical (1-5 carbon atoms);
or
R.sup.7 is hydrogen and R.sup.8 is (CH.sub.2)sub.p-B and p is 1-3 and
B is aryl selected from phenyl, phenyl mono-, di-, or tri-substituted by substituent from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, trifluoromethyl, cyano, di-lower alkylamino or their N-oxides, phenyloxy, phenyl, and methylsuphanyl, naphthyl, benzo>1,3!dioxol, or monocyclic aromatic heterocycle with 1 or 2 heteroatoms selected from N and O; and
R.sup.9 is hydrogen or halogen; and R.sup.10 is halogen or trifluoromethyl; as well as pharmaceutically acceptable salts of basic compounds of formula I.

### Claim 21 (depends on 19)

The method of claim 19 wherein said ophthalmic pharmaceutical composition is administered topically directly to the eye.

### Claim 22 (depends on 19)

The method of claim 19 wherein said ophthalmic pharmaceutical composition is administered as ophthalmic drops, ophthalmic salve, opthalmic ointment, ophthalmic spray, subconjunctival injection, or intravitreal injection, contact lens, conjunctival insert, ocular time release insert or sustained release implant.

### Claim 23 (depends on 19)

The method of claim 19 wherein said ophthalmic pharmaceutical composition is administered as ophthalmic drops in a dose of one to twelve drops to the eye per day at intervals of 1 to 12 times per day.

### Claim 24 (depends on 19)

The method of claim 19 wherein said ophthalmic pharmaceutical composition contains between about 0.001 nanograms per milliliter and 10.00 milligrams per milliliter of a 4-aminoquinoline derivative or a salt or isomer of a 4-aminoquinoline derivative in a pharmaceutically acceptable carrier.

### Claim 25 (depends on 19)

The method of claim 19 wherein said 4-aminoquinoline derivative is selected from the group consisting of and Amodiaquine, Chloroquine, and Hydroxychloroquine, and the derivatives, salts and isomers of Amodiaquine, Chloroquine, and Hydroxychloroquine.

### Claim 26

A method for treating ocular inflammation comprising topically applying to the eye an ophthalmic pharmaceutical composition comprising a pharmaceutically acceptable ophthalmic carrier and an ocular inflammation-treating amount of cletoquine, quinacrine (mepacrine), pyrimethamine, or mefloquine, or one of their pharmaceutically acceptable salts.

### Claim 27 (depends on 26)

The method of claim 26 wherein said ocular inflammation is related to a disease of the eye selected from the group consisting of allergy, infection, pain in the eye, non-infectious inflammation triggered by immunological factors, surgery, chemical or mechanical injury, injury due to exposure to radiation, infrared or ultraviolet rays, degenerative changes or dystrophies.

### Claim 28 (depends on 26)

The method of claim 26 wherein said ocular inflammation is related to a disease of the eye selected from the group consisting of urticaria, allergic conjunctivitis, keratitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, uveitis, iritis, iridocyclitis, scleritis, episcleritis, choroiditis, optic neuritis, Mooren's ulcer, ulcerative keratitis associated with rheumatoid arthritis, anterior uveitis, Thygeson's punctate keratitis, or other immunological reactions.

### Claim 29 (depends on 26)

The method of claim 26 wherein said ocular inflammation is related to an infection of the eye by one or more bacteria, virus, fungi, chlamydia, or amoeba.

### Claim 30 (depends on 26)

The method of claim 26 wherein said ocular inflammation is a uveitis selected from the group consisting of Behect's disease, pars planitis, idiopathic uveitis, ocular sarcoid, sympathetic ophthalmia, idiopathic vitritis, vitritis, or uveitis resulting from trauma.

### Claim 31

A method for treating retinitis pigmentosa comprising topically applying to the eye an ophthalmic pharmaceutical composition comprising a pharmaceutically acceptable ophthalmic carrier and an ocular inflammation-treating amount of one or more 4-aminoquinoline compounds, or one of their pharmaceutically acceptable analogues or salts.
